Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A

Pediatric Transplantation

Volumn 11, Issue 3, 2007, Pages 291-295

  Pape, Lars ^a   Ahlenstiel, Thurid ^a   Ehrich, Jochen H H ^a   Offner, Gisela ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CHOLESTEROL; CREATINE KINASE; CREATININE; CYCLOSPORIN A; EVEROLIMUS; LACTATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; LOW DRUG DOSE; MALE; OTITIS MEDIA; PNEUMONIA; SCHOOL CHILD; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WITHDRAWAL SYNDROME;

ADOLESCENT; BIOPSY; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS;

EID: 34147144078     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00651.x     Document Type: Article

References (25)

1. CECKA JM. The UNOS renal transplant registry. Clin Transpl 2001: 15: 1-18.
2. PAPE L, STREHLAU J, HENNE T, et al. Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 2002: 17: 276-280.
3. PAUL LC. Chronic renal transplant loss. Kidney Int 1995: 47: 1491-1499.
4. PAUL LC. Chronic allograft nephropathy: An update. Kidney Int 1999: 56: 783-793.
5. TULLIUS SG, TILNEY NL. Both alloantigen dependent independent factors influence chronic allograft rejection. Transplantation 1995: 59: 313-318.
6. HOSTETTER TH. Chronic transplant rejection. Kidney Int 1994: 46: 266-279.
7. MONACO AP, BURKE JF, FERGUSON RM, et al. Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999: 33: 150-160.
8. BUENO J, RAMIL C, GREEN M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002: 4: 279-290.
9. YILMAZ S, PAAVONEN R, HÄYRY P. Chronic rejection of rat renal allografts II: The impact of prolonged ischemia time on transplant histology. Transplantation 1992: 53: 823-827.
10. KOBASHIGAWA JA, KASISKE BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997: 63: 331-338.
11. WIGGER M, DRUCKLER E, MUSCHEITES J, STOLPE HJ. Course of glomerular filtration rate after renal transplantation and the influence of hypertension. Clin Nephrol 2001: 56: S30-S4.12
12. COSIO FG, PELLETIER RP, SEDMAK DD, et al. Pathologic classification of chronic allograft nephropathy: Pathogenic and prognostic implications. Transplantation 1999: 67: 690-696.
13. MYERS BD, ROSS J, NEWTON L, LUETSCHER J, PERLROTH M. Cyclosporine associated chronic nephropathy. N Engl J Med 1984: 311: 699-705.
14. HENNE T, LATTA K, STREHLAU J, PAPE L, EHRICH JH, OFFNER G. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003: 76: 1326-1330.
15. FILLER G, WOMILOJU T, FEBER J, LEPAGE N, CHRISTIANS U. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005: 5: 2005-2010.
16. HOYER PF, ETTENGER R, KOVARIK JM, et al., Everolimus Pediatric Study Group. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003: 75: 2082-2085.
17. SCHWARTZ GJ, BRION LP, SPITZER A. The use of plasma creatinine concentration for estimating glomerualr filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987: 34: 571-590.
18. KORECKA M, SOLARI SG, SHAW LM. Sensitive, high throughput HPLC-MS/MS method with on-line sample clean-up for everolimus measurement. Ther Drug Monit 2006: 28: 484-490.
19. VANDAMME-LOMBAERTS R, WEBB NJM, HOYER PF, et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant recipients. Pediatr Transplant 2002: 6: 147-152.
20. VITKO S, MARGREITER R, WEIMAR W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplantation 2005: 5: 2521-2530.
21. PASCUAL J. Concentration-controlled everolimus (Certican): Combination with reduced dose calcineurin inhibitors. Transplantation 2005: 15: S76-S79.
22. BRATTSROM C, WILCZEK H, TYDEN G, BOTTIGER Y, Sawe J, GROTH CG. Hyperlipidemia in renal transplant recipients treated with sirolimus. Transplantation 1998: 65: 1272-1274.
23. LETAVERNIER E, PE'RALDI MN, PARIENTE A, MORELON E, LEGENDRE C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005: 80: 1198-1203.
24. KOVARIK JM, DANTAL J, CIVATI G, et al. Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. Am J Transplant 2003: 3: 1576-1580.
25. KIRCHNER GI, MEIER-WIEDENBACH I, MANNS MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004: 43: 83-95.